URO-901-3007

A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)

MERSİN ÜNİVERSİTESİ

USA, Romania, Jordan, Slovakia, Türkiye 15.03.2023 –